Edition:
India

SCYNEXIS Inc (SCYX.OQ)

SCYX.OQ on NASDAQ Stock Exchange Global Market

1.86USD
22 Jan 2018
Change (% chg)

-- (--)
Prev Close
$1.86
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
31,032
52-wk High
$3.72
52-wk Low
$1.53

Chart for

About

SCYNEXIS, Inc. is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct... (more)

Overall

Beta: 0.40
Market Cap(Mil.): $65.20
Shares Outstanding(Mil.): 26.72
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.58
EPS (TTM): -- -- --
ROI: -- 14.84 10.60
ROE: -- 16.32 14.19

BRIEF-Scynexis Provides Corporate And SCY-078 Pipeline Update

* SCYNEXIS INC - ‍INTENDS TO INITIATE A PHASE 1 STUDY IN HEALTHY VOLUNTEERS IN Q3 2018, PENDING FDA'S REVIEW FOR LIPOSOMAL IV FORMULATION OF SCY-078​

05 Jan 2018

BRIEF-Scynexis reports third quarter 2017 financial results

* Scynexis reports third quarter 2017 financial results and provides company update

08 Nov 2017

BRIEF-Scynexis presents new data related to SCY-078​

* Scynexis Inc - ‍data demonstrates broad activity and potential clinical utility of SCY-078 against invasive candida and aspergillus infections Source text for Eikon: Further company coverage:

05 Oct 2017

BRIEF-Scynexis CEO Marco Taglietti​ buys 10,000 shares of co's common stock on Aug 15

* Scynexis Inc CEO‍ Marco Taglietti​ reports purchase of 10,000 shares of co's common stock on Aug 15 at $1.61 per share - SEC filing Source text: (http://bit.ly/2wj4Cck) Further company coverage:

17 Aug 2017

BRIEF-Scynexis Q2 loss per share $0.16

* Scynexis reports second quarter 2017 financial results and provides company update

09 Aug 2017

BRIEF-SCYNEXIS announces initiation of dosing in Phase 2 study evaluating oral SCY-078 in Vulvovaginal Candidiasis

* SCYNEXIS announces initiation of dosing in Phase 2 study evaluating oral SCY-078 in Vulvovaginal Candidiasis

04 Aug 2017

Earnings vs. Estimates